New thrombolytic praised for effectiveness
New thrombolytic praised for effectiveness
The American College of Cardiology is reporting a new clot-dissolver, saruplase, has outpaced streptokinase in a randomized study of 3,089 heart attack patients. Mortality rates were a full percentage point (5.7% vs. 6.7%) better at 30 days for patients given saruplase, and the overall rates of ischemic stroke were lower.
Researchers say while two treatments dominate the thrombolytic market - streptokinase and t-PA - a study comparing saruplase and t-PA is still forthcoming. Not yet on the market, saruplase is expected to be cheaper than t-PA (which is used more often in the U.S.) but probably more expensive than streptokinase should it eventually come to market. For details, call (800) 253-4636.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.